About alzamend neuro inc - ALZN
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.
ALZN At a Glance
Alzamend Neuro, Inc.
3480 Peachtree Road NE
Atlanta, Georgia 30326
| Phone | 1-844-722-6333 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -4,514,853.00 | |
| Sector | Health Technology | Employees | 7 | |
| Fiscal Year-end | 04 / 2026 | |||
| View SEC Filings |
ALZN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.166 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.286 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
ALZN Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -644,979.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ALZN Liquidity
| Current Ratio | 6.581 |
| Quick Ratio | 6.581 |
| Cash Ratio | 6.221 |
ALZN Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -172.501 |
| Return on Equity | -657.166 |
| Return on Total Capital | -113.775 |
| Return on Invested Capital | -657.166 |
ALZN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |